Tau acts as a mediator for Alzheimer's disease-related synaptic deficits

European Journal of Neuroscience

Volumn 39, Issue 7, 2014, Pages 1202-1213

  Liao, Dezhi ^a   Miller, Eric C ^a   Teravskis, Peter J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Amyloid beta; Amyloid cascade hypothesis; Dendritic spines; Soluble proteins; Synaptic dysfunction

Indexed keywords

AMYLOID BETA PROTEIN; CALCIUM; PHOSPHOPROTEIN; PRION PROTEIN; PROTEIN KINASE FYN; TAU PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; HISTOPATHOLOGY; HUMAN; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHY; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYNAPSE; SYNAPTIC DEFICIT; ANIMAL; GENETICS; METABOLISM; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; HUMANS; SIGNAL TRANSDUCTION; SYNAPSES; SYNAPTIC TRANSMISSION; TAU PROTEINS;

EID: 84898733006     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/ejn.12504     Document Type: Article

References (192)

1. Aarsland, D., Beyer, M.K. & Kurz, M.W. (2008) Dementia in Parkinson's disease. Curr. Opin. Neurol., 21, 676-682.
2. Abdul, H.M., Sama, M.A., Furman, J.L., Mathis, D.M., Beckett, T.L., Weidner, A.M., Patel, E.S., Baig, I., Murphy, M.P., LeVine, H., Kraner, S.D. & Norris, C.M. (2009) Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. J. Neurosci., 29, 12957-12969.
3. Alzheimer, A. (1907) Uber eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr., 64, 146-148.
4. Amadoro, G., Corsetti, V., Ciotti, M.T., Florenzano, F., Capsoni, S., Amato, G. & Calissano, P. (2011) Endogenous Aβ causes cell death via early tau hyperphosphorylation. Neurobiol. Aging, 32, 969-990.
5. Andorfer, C., Acker, C.M., Kress, Y., Hof, P.R., Duff, K. & Davies, P. (2005) Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J. Neurosci., 25, 5446-5454.
6. Arendt, T. (2009) Synaptic degeneration in Alzheimer's disease. Acta Neuropathol., 118, 167-179.
7. Arriagada, P.V., Growdon, J.H., Hedley-Whyte, E.T. & Hyman, B.T. (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology, 42, 631-639.
8. Ashe, K.H. & Zahs, K.R. (2010) Probing the biology of Alzheimer's disease in mice. Neuron, 66, 631-645.
9. Avila, J., Lucas, J.J., Perez, M. & Hernandez, F. (2004) Role of tau protein in both physiological and pathological conditions. Physiol. Rev., 84, 361-384.
10. Bennett, D.A., Schneider, J.A., Wilson, R.S., Bienias, J.L. & Arnold, S.E. (2004) Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch. Neurol., 61, 378-384.
11. Bennett, D.A., Schneider, J.A., Arvanitakis, Z., Kelly, J.F., Aggarwal, N.T., Shah, R.C. & Wilson, R.S. (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology, 66, 1837-1844.
12. Bhat, R.V., Budd Haeberlein, S.L. & Avila, J. (2004) Glycogen synthase kinase 3: a drug target for CNS therapies. J. Neurochem., 89, 1313-1317.
13. Billings, L.M., Oddo, S., Green, K.N., McGaugh, J.L. & LaFerla, F.M. (2005) Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron, 45, 675-688.
14. Bittner, T., Fuhrmann, M., Burgold, S., Ochs, S.M., Hoffmann, N., Mitteregger, G., Kretzschmar, H., LaFerla, F.M. & Herms, J. (2010) Multiple events lead to dendritic spine loss in triple transgenic Alzheimer's disease mice. PLoS One, 5, e15477.
15. Blennow, K., de Leon, M.J. & Zetterberg, H. (2006) Alzheimer's disease. Lancet, 368, 387-403.
16. Boekhoorn, K., Terwel, D., Biemans, B., Borghgraef, P., Wiegert, O., Ramakers, G.J.A., de Vos, K., Krugers, H., Tomiyama, T., Mori, H., Joels, M., Van Leuven, F. & Lucassen, P.J. (2006) Improved long-term potentiation and memory in young tau-P301L transgenic mice before onset of hyperphosphorylation and tauopathy. J. Neurosci., 26, 3514-3523.
17. Bolmont, T., Clavaguera, F., Meyer-Luehmann, M., Herzig, M.C., Radde, R., Staufenbiel, M., Lewis, J., Hutton, M., Tolnay, M. & Jucker, M. (2007) Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x tau transgenic mice. Am. J. Pathol., 171, 2012-2020.
18. Bondolfi, L., Calhoun, M., Ermini, F., Kuhn, H.G., Wiederhold, K.-H., Walker, L., Staufenbiel, M. & Jucker, M. (2002) Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J. Neurosci., 22, 515-522.
19. Brandt, R., Hundelt, M. & Shahani, N. (2005) Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim. Biophys. Acta, 1739, 331-354.
20. Buée, L., Bussière, T., Buée-Scherrer, V., Delacourte, A. & Hof, P.R. (2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev., 33, 95-130.
21. Buerger, K., Ewers, M., Andreasen, N., Zinkowski, R., Ishiguro, K., Vanmechelen, E., Teipel, S.J., Graz, C., Blennow, K. & Hampel, H. (2005) Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology, 65, 1502-1503.
22. Busche, M.A., Eichhoff, G., Adelsberger, H., Abramowski, D., Wiederhold, K.H., Haass, C., Staufenbiel, M., Konnerth, A. & Garaschuk, O. (2008) Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science, 321, 1686-1689.
23. Byrne, M.J., Waxham, M.N. & Kubota, Y. (2011) The impacts of geometry and binding on CaMKII diffusion and retention in dendritic spines. J. Comput. Neurosci., 31, 1-12.
24. Castello, M.A. & Soriano, S. (2013) Rational heterodoxy: cholesterol reformation of the amyloid doctrine. Ageing Res. Rev., 12, 282-288.
25. Chapman, P.F., White, G.L., Jones, M.W., Cooper-Blacketer, D., Marshall, V.J., Irizarry, M., Younkin, L., Good, M.A., Bliss, T.V., Hyman, B.T., Younkin, S.G. & Hsiao, K.K. (1999) Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci., 2, 271-276.
26. Chen, Q.-S., Wei, W.-Z., Shimahara, T. & Xie, C.-W. (2002) Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol. Learn. Mem., 77, 354-371.
27. Chen, C., Li, X.H., Tu, Y., Sun, H.T., Liang, H.Q., Cheng, S.X. & Zhang, S. (2013) Aβ-AGE aggravates cognitive deficit in rats via RAGE pathway. Neuroscience, 257, 1-10.
28. Cheng, I.H., Scearce-Levie, K., Legleiter, J., Palop, J.J., Gerstein, H., Bien-Ly, N., Puoliväli, J., Lesné, S., Ashe, K.H., Muchowski, P.J. & Mucke, L. (2007) Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem., 282, 23818-23828.
29. Cingolani, L.A. & Goda, Y. (2008) Actin in action: the interplay between the actin cytoskeleton and synaptic efficacy. Nat. Rev. Neurosci., 9, 344-356.
30. Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-Wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., Hyslop St George, P. & Selkoe, D.J. (1997) Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat. Med., 3, 67-72.
31. Cohen, R.M., Rezai-Zadeh, K., Weitz, T.M., Rentsendorj, A., Gate, D., Spivak, I., Bholat, Y., Vasilevko, V., Glabe, C.G., Breunig, J.J., Rakic, P., Davtyan, H., Agadjanyan, M.G., Kepe, V., Barrio, J.R., Bannykh, S., Szekely, C.A., Pechnick, R.N. & Town, T. (2013) A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J. Neurosci., 33, 6245-6256.
32. Colton, C.A., Wilcock, D.M., Wink, D.A., Davis, J., Van Nostrand, W.E. & Vitek, M.P. (2008) The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP. J. Alzheimers Dis., 15, 571-587.
33. Crimins, J.L., Pooler, A., Polydoro, M., Luebke, J.I. & Spires-Jones, T.L. (2013) The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing Res. Rev., 12, 757-763.
34. Cuchillo-Ibáñez, I., Balmaceda, V., Botella-López, A., Rabano, A., Avila, J. & Sáez-Valero, J. (2013) Beta-amyloid impairs reelin signaling. PLoS One, 8, e72297.
35. D'Amelio, M., Cavallucci, V., Middei, S., Marchetti, C., Pacioni, S., Ferri, A., Diamantini, A., De Zio, D., Carrara, P., Battistini, L., Moreno, S., Bacci, A., Ammassari-Teule, M., Marie, H. & Cecconi, F. (2011) Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat. Neurosci., 14, 69-76.
36. Davies, C.A., Mann, D.M., Sumpter, P.Q. & Yates, P.O. (1987) A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J. Neurol. Sci., 78, 151-164.
37. De Felice, F.G., Wu, D., Lambert, M.P., Fernandez, S.J., Velasco, P.T., Lacor, P.N., Bigio, E.H., Jerecic, J., Acton, P.J., Shughrue, P.J., Chen-Dodson, E., Kinney, G.G. & Klein, W.L. (2008) Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol. Aging, 29, 1334-1347.
38. Decker, H., Jürgensen, S., Adrover, M.F., Brito-Moreira, J., Bomfim, T.R., Klein, W.L., Epstein, A.L., De Felice, F.G., Jerusalinsky, D. & Ferreira, S.T. (2010) N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers. J. Neurochem., 115, 1520-1529.
39. DeKosky, S.T. & Scheff, S.W. (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol., 27, 457-464.
40. Delacourte, A., Sergeant, N., Champain, D., Wattez, A., Maurage, C.-A., Lebert, F., Pasquier, F. & David, J.-P. (2002) Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. Neurology, 59, 398-407.
41. Dell'Acqua, M.L., Smith, K.E., Gorski, J.A., Horne, E.A., Gibson, E.S. & Gomez, L.L. (2006) Regulation of neuronal PKA signaling through AKAP targeting dynamics. Eur. J. Cell Biol., 85, 627-633.
42. DeStrooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., von Figura, K. & Van Leuven, F. (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature, 391, 387-390.
43. Dineley, K.T., Hogan, D., Zhang, W.-R. & Taglialatela, G. (2007) Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol. Learn. Mem., 88, 217-224.
44. Eisele, Y.S. (2013) From soluble aβ to progressive aβ aggregation: could prion-like templated misfolding play a role? Brain Pathol., 23, 333-341.
45. Endres, K. & Reinhradt, S. (2013) ER-stress in Alzheimer's disease: turning the scale? Am. J. Neurodegener. Dis., 2, 247-265.
46. Fitzjohn, S.M., Doherty, A.J. & Collingridge, G.L. (2008) The use of the hippocampal slice preparation in the study of Alzheimer's disease. Eur. J. Pharmacol., 585, 50-59.
47. Fonseca, A.C.R.G., Ferreiro, E., Oliveira, C.R., Cardoso, S.M. & Pereira, C.F. (2013) Activation of the endoplasmic reticulum stress response by the amyloid-beta 1-40 peptide in brain endothelial cells. Biochim. Biophys. Acta, 1832, 2191-2203.
48. Fotuhi, M., Hachinski, V. & Whitehouse, P.J. (2009) Changing perspectives regarding late-life dementia. Nat. Rev. Neurol., 5, 649-658.
49. Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T. & Gillespie, F. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature, 373, 523-527.
50. Gendron, T.F. & Petrucelli, L. (2009) The role of tau in neurodegeneration. Mol. Neurodegener., 4, 13.
51. Gervais, F.G., Xu, D., Robertson, G.S., Vaillancourt, J.P., Zhu, Y., Huang, J., LeBlanc, A., Smith, D., Rigby, M., Shearman, M.S., Clarke, E.E., Zheng, H., Van Der Ploeg, L.H., Ruffolo, S.C., Thornberry, N.A., Xanthoudakis, S., Zamboni, R.J., Roy, S. & Nicholson, D.W. (1999) Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell, 97, 395-406.
52. Gilman, S., Koller, M., Black, R.S., Jenkins, L., Griffith, S.G., Fox, N.C., Eisner, L., Kirby, L., Rovira, M.B., Forette, F., Orgogozo, J.-M. & AN1792(QS-21)-201 Study Team (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 64, 1553-1562.
53. Golde, T.E., Petrucelli, L. & Lewis, J. (2010) Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp. Neurol., 223, 252-266.
54. Gómez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J.H., Petersen, R.C., Parisi, J.E. & Hyman, B.T. (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol., 41, 17-24.
55. Gonatas, N.K., Anderson, W. & Evangelista, I. (1967) The contribution of altered synapses in the senile plaque: an electron microscopic study in Alzheimer's dementia. J. Neuropath. Exp. Neur., 26, 25-39.
56. Götz, J., Probst, A., Spillantini, M.G., Schäfer, T., Jakes, R., Bürki, K. & Goedert, M. (1995) Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J., 14, 1304-1313.
57. Götz, J., Chen, F., van Dorpe, J. & Nitsch, R.M. (2001) Formation of neurofibrillary tangles in P301 l tau transgenic mice induced by Abeta 42 fibrils. Science, 293, 1491-1495.
58. Green, K.N. (2009) Calcium in the initiation, progression and as an effector of Alzheimer's disease pathology. J. Cell Mol. Med., 13, 2787-2799.
59. Green, R.C., Schneider, L.S., Amato, D.A., Beelen, A.P., Wilcock, G., Swabb, E.A., Zavitz, K.H. & Tarenflurbil Phase 3 Study Group (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA, 302, 2557-2564.
60. Grundke-Iqbal, I., Iqbal, K., Tung, Y.C., Quinlan, M., Wisniewski, H.M. & Binder, L.I. (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA, 83, 4913-4917.
61. Gureviciene, I., Ikonen, S., Gurevicius, K., Sarkaki, A., van Groen, T., Pussinen, R., Ylinen, A. & Tanila, H. (2004) Normal induction but accelerated decay of LTP in APP + PS1 transgenic mice. Neurobiol. Dis., 15, 188-195.
62. Haass, C. & Selkoe, D.J. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol., 8, 101-112.
63. Haass, C., Schlossmacher, M.G., Hung, A.Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B.L., Lieberburg, I., Koo, E.H., Schenk, D. & Teplow, D.B. (1992) Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature, 359, 322-325.
64. Haggerty, T., Credle, J., Rodriguez, O., Wills, J., Oaks, A.W., Masliah, E. & Sidhu, A. (2011) Hyperphosphorylated tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease. Eur. J. Neurosci., 33, 1598-1610.
65. Hampel, H., Bürger, K., Pruessner, J.C., Zinkowski, R., DeBernardis, J., Kerkman, D., Leinsinger, G., Evans, A.C., Davies, P., Möller, H.-J. & Teipel, S.J. (2005) Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch. Neurol., 62, 770-773.
66. Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K. & Minthon, L. (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol., 5, 228-234.
67. Hardy, J. & Allsop, D. (1991) Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci., 12, 383-388.
68. Hardy, J.A. & Higgins, G.A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science, 256, 184-185.
69. Hardy, J. & Selkoe, D.J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297, 353-356.
70. Heinonen, O., Soininen, H., Sorvari, H., Kosunen, O., Paljärvi, L., Koivisto, E. & Riekkinen, P.J. (1995) Loss of synaptophysin-like immunoreactivity in the hippocampal formation is an early phenomenon in Alzheimer's disease. Neuroscience, 64, 375-384.
71. van Helmond, Z., Miners, J.S., Kehoe, P.G. & Love, S. (2010) Oligomeric Abeta in Alzheimer's disease: relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy. Brain Pathol., 20, 468-480.
72. Hermann, D., Mezler, M., Muller, M.K., Wicke, K., Gross, G., Draguhn, A., Bruehl, C. & Nimmrich, V. (2013) Synthetic Aβ oligomers (Aβ(1-42) globulomer) modulate presynaptic calcium currents: prevention of Aβ-induced synaptic deficits by calcium channel blockers. Eur. J. Pharmacol., 702, 44-55.
73. Ho, A. & Shen, J. (2011) Presenilins in synaptic function and disease. Trends Mol. Med., 17, 617-624.
74. Holcomb, L., Gordon, M.N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., Sanders, S., Zehr, C., O'Campo, K., Hardy, J., Prada, C.M., Eckman, C., Younkin, S., Hsiao, K. & Duff, K. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med., 4, 97-100.
75. Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R.W., Bullock, R., Love, S., Neal, J.W., Zotova, E. & Nicoll, J.A. (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, 372, 216-223.
76. Hoover, B.R., Reed, M.N., Su, J., Penrod, R.D., Kotilinek, L.A., Grant, M.K., Pitstick, R., Carlson, G.A., Lanier, L.M., Yuan, L.-L., Ashe, K.H. & Liao, D. (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron, 68, 1067-1081.
77. Hsia, A.Y., Masliah, E., McConlogue, L., Yu, G.Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R.C., Nicoll, R.A. & Mucke, L. (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA, 96, 3228-3233.
78. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F. & Cole, G. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science, 274, 99-102.
79. Hsieh, H., Boehm, J., Sato, C., Iwatsubo, T., Tomita, T., Sisodia, S. & Malinow, R. (2006) AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron, 52, 831-843.
80. Huang, J.K., Ma, P.L., Ji, S.Y., Zhao, X.L., Tan, J.X., Sun, X.J. & Huang, F.D. (2013) Age-dependent alterations in the presynaptic active zone in a Drosophila model of Alzheimer's disease. Neurobiol. Dis., 51, 161-167.
81. Hulette, C.M., Welsh-Bohmer, K.A., Murray, M.G., Saunders, A.M., Mash, D.C. & Mcintyre, L.M. (1998) Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical alzheimer disease in cognitively normal individuals. J. Neuropath. Exp. Neur., 57, 1168.
82. Irwin, D.J., Lee, V.M.Y. & Trojanowski, J.Q. (2013) Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat. Rev. Neurosci., 14, 626-636.
83. Ishizawa, T., Mattila, P., Davies, P., Wang, D. & Dickson, D.W. (2003) Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J. Neuropath. Exp. Neur., 62, 389-397.
84. Ittner, L.M., Ke, Y.D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B.C., Christie, M.J., Napier, I.A., Eckert, A., Staufenbiel, M., Hardeman, E. & Götz, J. (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell, 142, 387-397.
85. Jankowsky, J.L., Slunt, H.H., Ratovitski, T., Jenkins, N.A., Copeland, N.G. & Borchelt, D.R. (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng., 17, 157-165.
86. Jo, J., Whitcomb, D.J., Olsen, K.M., Kerrigan, T.L., Lo, S.-C., Bru-Mercier, G., Dickinson, B., Scullion, S., Sheng, M., Collingridge, G. & Cho, K. (2011) Aβ(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β. Nat. Neurosci., 14, 545-547.
87. Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S. & Malinow, R. (2003) APP processing and synaptic function. Neuron, 37, 925-937.
88. Karran, E., Mercken, M. & De Strooper, B. (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov., 10, 698-712.
89. Kawakami, F., Suzuki, M., Shimada, N., Kagiya, G., Ohta, E., Tamura, K., Maruyama, H. & Ichikawa, T. (2011) Stimulatory effect of α-synuclein on the tau-phosphorylation by GSK-3β. FEBS J., 278, 4895-4904.
90. Kessels, H.W., Nabavi, S. & Malinow, R. (2013) Metabotropic NMDA receptor function is required for β-amyloid-induced synaptic depression. Proc. Natl. Acad. Sci. USA, 110, 4033-4038.
91. Kins, S., Crameri, A., Evans, D.R., Hemmings, B.A., Nitsch, R.M. & Götz, J. (2001) Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J. Biol. Chem., 276, 38193-38200.
92. Kovacs, G.G., Alafuzoff, I., Al-Sarraj, S., Arzberger, T., Bogdanovic, N., Capellari, S., Ferrer, I., Gelpi, E., Kövari, V., Kretzschmar, H., Nagy, Z., Parchi, P., Seilhean, D., Soininen, H., Troakes, C. & Budka, H. (2008) Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement. Geriatr. Cogn., 26, 343-350.
93. Krafft, G.A. & Klein, W.L. (2010) ADDLs and the signaling web that leads to Alzheimer's disease. Neuropharmacology, 59, 230-242.
94. Kuchibhotla, K.V., Goldman, S.T., Lattarulo, C.R., Wu, H.-Y., Hyman, B.T. & Bacskai, B.J. (2008) Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron, 59, 214-225.
95. Lacor, P.N., Buniel, M.C., Furlow, P.W., Clemente, A.S., Velasco, P.T., Wood, M., Viola, K.L. & Klein, W.L. (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci., 27, 796-807.
96. Langa, K.M., Foster, N.L. & Larson, E.B. (2004) Mixed dementia: emerging concepts and therapeutic implications. JAMA, 292, 2901-2908.
97. Lanz, T.A., Carter, D.B. & Merchant, K.M. (2003) Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol. Dis., 13, 246-253.
98. Larson, M.E. & Lesné, S.E. (2012) Soluble Aβ oligomer production and toxicity. J. Neurochem., 120(Suppl 1), 125-139.
99. Larson, M., Sherman, M.A., Amar, F., Nuvolone, M., Schneider, J.A., Bennett, D.A., Aguzzi, A. & Lesné, S.E. (2012) The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. J. Neurosci., 32, 16857-16871.
100. Laurén, J. (2014) Cellular prion protein as a therapeutic target in Alzheimer's disease. J. Alzheimers Dis., 38, 227-244.
101. Laurén, J., Gimbel, D.A., Nygaard, H.B., Gilbert, J.W. & Strittmatter, S.M. (2009) Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature, 457, 1128-1132.
102. Lee, S.-J.R., Escobedo-Lozoya, Y., Szatmari, E.M. & Yasuda, R. (2009) Activation of CaMKII in single dendritic spines during long-term potentiation. Nature, 458, 299-304.
103. Lei, P., Ayton, S., Bush, A.I. & Adlard, P.A. (2011) GSK-3 in neurodegenerative diseases. Int. J. Alzheimers Dis., 2011, 189246.
104. Leroy, K., Ando, K., Laporte, V., Dedecker, R., Suain, V., Authelet, M., Héraud, C., Pierrot, N., Yilmaz, Z., Octave, J.-N. & Brion, J.-P. (2012) Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. Am. J. Pathol., 181, 1928-1940.
105. Lesné, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M. & Ashe, K.H. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature, 440, 352-357.
106. Lewis, J., Dickson, D.W., Lin, W.L., Chisholm, L., Corral, A., Jones, G., Yen, S.H., Sahara, N., Skipper, L., Yager, D., Eckman, C., Hardy, J., Hutton, M. & McGowan, E. (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science, 293, 1487-1491.
107. Li, S., Jin, M., Koeglsperger, T., Shepardson, N., Shankar, G. & Selkoe, D. (2011) Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J. Neurosci., 31, 6627-6638.
108. Li, X.H., Lv, B.L., Xie, J.Z., Liu, J., Zhou, X.W. & Wang, J.Z. (2012) AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol. Aging, 33, 1-11.
109. Lovestone, S., Reynolds, C.H., Latimer, D., Davis, D.R., Anderton, B.H., Gallo, J.M., Hanger, D., Mulot, S., Marquardt, B. & Stabel, S. (1994) Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfect mammalian cells. Curr. Biol., 4, 1077-1086.
110. Ly, P.T., Wu, Y., Zou, H., Wang, R., Zhou, W., Kinoshita, A., Zhang, M., Yang, Y., Cai, F., Woodgett, J. & Song, W. (2013) Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J. Clin. Invest., 123, 224-235.
111. Mairet-Coello, G., Courchet, J., Pieraut, S., Courchet, V., Maximov, A. & Polleux, F. (2013) The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through tau phosphorylation. Neuron, 78, 94-408.
112. Malenka, R.C. & Bear, M.F. (2004) LTP and LTD: an embarrassment of riches. Neuron, 44, 5-21.
113. Masliah, E., Terry, R.D., DeTeresa, R.M. & Hansen, L.A. (1989) Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci. Lett., 103, 234-239.
114. Masters, C.L., Simms, G., Weinman, N.A., Multhaup, G., McDonald, B.L. & Beyreuther, K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA, 82, 4245-4249.
115. Matsuzaki, M., Honkura, N., Ellis-Davies, G.C.R. & Kasai, H. (2004) Structural basis of long-term potentiation in single dendritic spines. Nature, 429, 761-766.
116. McBrayer, M. & Nixon, R.A. (2013) Lysosome and calcium dysregulation in Alzheimer's disease: partners in crime. Biochem. Soc. Trans., 41, 1495-1502.
117. McGeer, P.L. & McGeer, E.G. (2013) The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta. Neuropathol., 126, 479-497.
118. McLean, C.A., Cherny, R.A., Fraser, F.W., Fuller, S.J., Smith, M.J., Beyreuther, K., Bush, A.I. & Masters, C.L. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol., 46, 860-866.
119. Miller, E.C., Zhang, L., Dummer, B.W., Cariveau, D.R., Loh, H.H., Law, P.Y. & Liao, D. (2012) Differential modulation of drug-induced structural and functional plasticity of dendritic spines. Mol. Pharmacol., 82, 333-343.
120. Miller, E.C., Teravskis, P., Dummer, B.W., Zhao, X., Huganir, R.L. & Liao, D. (2014) Tau phosphorylation and tau mislocalization mediate soluble Aβ oligomer-induced AMPA glutamate receptor signaling deficits. Eur. J. Neurosci., doi: 10.1111/ejn.12507. [Epub ahead of print].
121. Morris, M., Maeda, S., Vossel, K. & Mucke, L. (2011) The many faces of tau. Neuron, 70, 410-426.
122. Mucke, L., Masliah, E., Yu, G.Q., Mallory, M., Rockenstein, E.M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K. & McConlogue, L. (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci., 20, 4050-4058.
123. Mulkey, R.M., Endo, S., Shenolikar, S. & Malenka, R.C. (1994) Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature, 369, 486-488.
124. Näslund, J., Haroutunian, V., Mohs, R., Davis, K.L., Davies, P., Greengard, P. & Buxbaum, J.D. (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA, 283, 1571-1577.
125. Nikkel, A.L., Martino, B., Markosyan, S., Brederson, J.D., Medeiros, R., Moeller, A. & Bitner, R.S. (2012) The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo. Neuropharmacology, 63, 606-612.
126. Noh, M.-Y., Chun, K., Kang, B.Y., Kim, H., Park, J.-S., Lee, H.-C., Kim, Y.-H., Ku, S. & Kim, S.H. (2013) Newly developed glycogen synthase kinase-3 (GSK-3) inhibitors protect neuronal cells death in amyloid-beta induced cell model and in a transgenic mouse model of Alzheimer's disease. Biochem. Bioph. Res. Co., 435, 274-281.
127. Nukina, N. & Ihara, Y. (1986) One of the antigenic determinants of paired helical filaments is related to tau protein. J. Biochem., 99, 1541-1544.
128. Nussbaum, J.M., Seward, M.E. & Bloom, G.S. (2013) Alzheimer disease: a tale of two prions. Prion, 7, 14-19.
129. Oddo, S., Caccamo, A., Kitazawa, M., Tseng, B.P. & LaFerla, F.M. (2003) Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol. Aging, 24, 1063-1070.
130. Oddo, S., Billings, L., Kesslak, J.P., Cribbs, D.H. & LaFerla, F.M. (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron, 43, 321-332.
131. Oddo, S., Vasilevko, V., Caccamo, A., Kitazawa, M., Cribbs, D.H. & LaFerla, F.M. (2006) Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem., 281, 39413-39423.
132. Østergaard, L., Aamand, R., Gutiérrez-Jiménez, E., Ho, Y.C., Blicher, J.U., Madsen, S.M., Nagenthiraja, K., Dalby, R.B., Drasbek, K.R., Møller, A., Brændgaard, H., Mouridsen, K., Jespersen, S.N., Jensen, M.S. & West, M.J. (2013) The capillary dysfunction hypothesis of Alzheimer's disease. Neurobiol. Aging, 34, 1018-1031.
133. Padmanabhan, J., Levy, M., Dickson, D.W. & Potter, H. (2006) Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Brain, 129, 3020-3034.
134. Papasozomenos, S.C. & Binder, L.I. (1987) Phosphorylation determines two distinct species of tau in the central nervous system. Cell Motil. Cytoskel., 8, 210-226.
135. Patterson, M. & Yasuda, R. (2011) Signalling pathways underlying structural plasticity of dendritic spines. Brit. J. Pharmacol., 163, 1626-1638.
136. Perez-Cruz, C., Nolte, M.W., van Gaalen, M.M., Rustay, N.R., Termont, A., Tanghe, A., Kirchhoff, F. & Ebert, U. (2011) Reduced spine density in specific regions of CA1 pyramidal neurons in two transgenic mouse models of Alzheimer's disease. J. Neurosci., 31, 3926-3934.
137. Phiel, C.J., Wilson, C.A., Lee, V.M. & Klein, P.S. (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature, 423, 435-439.
138. Price, J.L., McKeel, D.W., Buckles, V.D., Roe, C.M., Xiong, C., Grundman, M., Hansen, L.A., Petersen, R.C., Parisi, J.E., Dickson, D.W., Smith, C.D., Davis, D.G., Schmitt, F.A., Markesbery, W.R., Kaye, J., Kurlan, R., Hulette, C., Kurland, B.F., Higdon, R., Kukull, W. & Morris, J.C. (2009) Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol. Aging, 30, 1026-1036.
139. Ramsden, M., Kotilinek, L., Forster, C., Paulson, J., McGowan, E., SantaCruz, K., Guimaraes, A., Yue, M., Lewis, J., Carlson, G., Hutton, M. & Ashe, K.H. (2005) Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J. Neurosci., 25, 10637-10647.
140. Reichmann, H., Schneider, C. & Löhle, M. (2009) Non-motor features of Parkinson's disease: depression and dementia. Parkinsonism Relat. D., 15(Suppl 3), S87-S92.
141. Reitz, C. (2012) Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int. J. Alzheimers Dis., 2012, 369808.
142. Roberson, E.D., Scearce-Levie, K., Palop, J.J., Yan, F., Cheng, I.H., Wu, T., Gerstein, H., Yu, G.-Q. & Mucke, L. (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science, 316, 750-754.
143. Roberson, E.D., Halabisky, B., Yoo, J.W., Yao, J., Chin, J., Yan, F., Wu, T., Hamto, P., Devidze, N., Yu, G.Q., Palop, J.J., Noebels, J.L. & Mucke, L. (2011) Amyloid-/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci., 31, 700-711.
144. Rupp, N.J., Wegenast-Braun, B.M., Radde, R., Calhoun, M.E. & Jucker, M. (2011) Early onset amyloid lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic mice. Neurobiol. Aging, 32, 2324.e1-2324.e6.
145. Russell, C.L., Semerdjieva, S., Empson, R.M., Austen, B.M., Beesley, P.W. & Alifragis, P. (2012) Amyloid-β acts as a regulator of neurotransmitter release disrupting the interaction between synaptophysin and VAMP2. PLoS One, 7, e403201.
146. Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., Forster, C., Yue, M., Orne, J., Janus, C., Mariash, A., Kuskowski, M., Hyman, B., Hutton, M. & Ashe, K.H. (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science, 309, 476-481.
147. Schindowski, K., Bretteville, A., Leroy, K., Bégard, S., Brion, J.-P., Hamdane, M. & Buée, L. (2006) Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am. J. Pathol., 169, 599-616.
148. Schneider, J.A. (2009) High blood pressure and microinfarcts: a link between vascular risk factors, dementia, and clinical Alzheimer's disease. J. Am. Geriatr. Soc., 57, 2146-2147.
149. Selkoe, D.J. (2002) Alzheimer's disease is a synaptic failure. Science, 298, 789-791.
150. Shankar, G.M., Bloodgood, B.L., Townsend, M., Walsh, D.M., Selkoe, D.J. & Sabatini, B.L. (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci., 27, 2866-2875.
151. Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A., Rowan, M.J., Lemere, C.A., Regan, C.M., Walsh, D.M., Sabatini, B.L. & Selkoe, D.J. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med., 14, 837-842.
152. Shen, J. (2013) Function and dysfunction of presenilin. Neurodegener. Dis., 13, 61-63.
153. Sheng, M., Sabatini, B.L. & Sudhof, T.C. (2012) Synapses and Alzheimer's disease. Cold Spring Harb. Perspect. Biol., 4, 1-18.
154. Shrestha, B.R., Vitolo, O.V., Joshi, P., Lordkipanidze, T., Shelanski, M. & Dunaevsky, A. (2006) Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons. Mol. Cell. Neurosci., 33, 274-282.
155. Shukla, V., Skuntz, S. & Pant, H.C. (2012) Deregulated Cdk5 activity is involved in inducing Alzheimer's disease. Arch. Med. Res., 43, 435-439.
156. Snyder, E.M., Nong, Y., Almeida, C.G., Paul, S., Moran, T., Choi, E.Y., Nairn, A.C., Salter, M.W., Lombroso, P.J., Gouras, G.K. & Greengard, P. (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat. Neurosci., 8, 1051-1058.
157. Spires, T.L., Orne, J.D., SantaCruz, K., Pitstick, R., Carlson, G.A., Ashe, K.H. & Hyman, B.T. (2006) Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am. J. Pathol., 168, 1598-1607.
158. Spittaels, K., Van den Haute, C., van Dorpe, J., Bruynseels, K., Vandezande, K., Laenen, I., Geerts, H., Mercken, M., Sciot, R., Van Lommel, A., Loos, R. & Van Leuven, F. (1999) Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am. J. Pathol., 155, 2153-2165.
159. Stadelmann, C., Deckwerth, T.L., Srinivasan, A., Bancher, C., Brück, W., Jellinger, K. & Lassmann, H. (1999) Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am. J. Pathol., 155, 1459-1466.
160. Stark, D.T. & Bazan, N.G. (2011) Synaptic and extrasynaptic NMDA receptors differentially modulate neuronal COX-2 function, lipid peroxidation, and neuroprotection. J. Neurosci., 31, 13710-13721.
161. Steinhilb, M.L., Dias-Santagata, D., Mulkearns, E.E., Shulman, J.M., Biernat, J., Mandelkow, E.-M. & Feany, M.B. (2007) S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila. J. Neurosci. Res., 85, 1271-1278.
162. Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P.A., Waridel, C., Calhoun, M.E., Jucker, M., Probst, A., Staufenbiel, M. & Sommer, B. (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA, 94, 13287-13292.
163. Svenningsson, P., Westman, E., Ballard, C. & Aarsland, D. (2012) Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol., 11, 697-707.
164. Swerdlow, R.H., Burns, J.M. & Khan, S.M. (2010) The Alzheimer's disease mitochondrial cascade hypothesis. J. Alzheimers Dis., 20, S265-S279.
165. Swerdlow, R.H., Burns, J.M. & Khan, S.M. (2013) The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim. Biophys. Acta, doi: 10.1016/j.bbadis.2013.09.010. [Epub ahead of print].
166. Sze, C.I., Troncoso, J.C., Kawas, C., Mouton, P., Price, D.L. & Martin, L.J. (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J. Neuropath. Exp. Neur., 56, 933-944.
167. Taglialatela, G., Hogan, D., Zhang, W.-R. & Dineley, K.T. (2009) Intermediate- and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition. Behav. Brain Res., 200, 95-99.
168. Takashima, A., Noguchi, K., Michel, G., Mercken, M., Hoshi, M., Ishiguro, K. & Imahori, K. (1996) Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci. Lett., 203, 33-36.
169. Tanzi, R.E. & Bertram, L. (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell, 120, 545-555.
170. Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., DeTeresa, R., Hill, R., Hansen, L.A. & Katzman, R. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol., 30, 572-580.
171. Tomiyama, T., Matsuyama, S., Iso, H., Umeda, T., Takuma, H., Ohnishi, K., Ishibashi, K., Teraoka, R., Sakama, N., Yamashita, T., Nishitsuji, K., Ito, K., Shimada, H., Lambert, M.P., Klein, W.L. & Mori, H. (2010) A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J. Neurosci., 30, 4845-4856.
172. Um, J.W. & Strittmatter, S.M. (2013) Amyloid-β induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. Prion, 7, 37-41.
173. Um, J.W., Kaufman, A.C., Kostylev, M., Heiss, J.K., Stagi, M., Takahashi, H., Kerrisk, M.E., Vortmeyer, A., Wisniewski, T., Koleske, A.J., Gunther, E.C., Nygaard, H.B. & Strittmatter, S.M. (2013) Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron, 79, 887-902.
174. Verret, L., Mann, E.O., Hang, G.B., Barth, A.M., Cobos, I., Ho, K., Devidze, N., Masliah, E., Kreitzer, A.C., Mody, I., Mucke, L. & Palop, J.J. (2012) Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell, 149, 708-721.
175. Vossel, K.A., Zhang, K., Brodbeck, J., Daub, A.C., Sharma, P., Finkbeiner, S., Cui, B. & Mucke, L. (2010) Tau reduction prevents Abeta-induced defects in axonal transport. Science, 330, 198.
176. Wagner, U., Utton, M., Gallo, J.M. & Miller, C.C. (1996) Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J. Cell Sci., 109(Pt 6), 1537-1543.
177. Wang, J.Z., Grundke-Iqbal, I. & Iqbal, K. (1996) Restoration of biological activity of Alzheimer abnormally phosphorylated tau by dephosphorylation with protein phosphatase-2A, -2B and -1. Mol. Brain Res., 38, 200-208.
178. Wang, J.Z., Wu, Q., Smith, A., Grundke-Iqbal, I. & Iqbal, K. (1998) Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS Lett., 436, 28-34.
179. Wang, J.-Z., Xia, Y.-Y., Grundke-Iqbal, I. & Iqbal, K. (2013) Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J. Alzheimers Dis., 33(Suppl 1), S123-S139.
180. Westerman, M.A., Cooper-Blacketer, D., Mariash, A., Kotilinek, L., Kawarabayashi, T., Younkin, L.H., Carlson, G.A., Younkin, S.G. & Ashe, K.H. (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci., 22, 1858-1867.
181. Wilcock, D.M., Lewis, M.R., Van Nostrand, W.E., Davis, J., Previti, M.L., Gharkholonarehe, N., Vitek, M.P. & Colton, C.A. (2008) Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J. Neurosci., 28, 1537-1545.
182. Wischik, C.M., Harrington, C.R. & Storey, J.M. (2013) Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochem. Pharmacol., doi: 10.1016/j.bcp.2013.12.008. [Epub ahead of print].
183. Wu, H.-Y., Hudry, E., Hashimoto, T., Kuchibhotla, K., Rozkalne, A., Fan, Z., Spires-Jones, T., Xie, H., Arbel-Ornath, M., Grosskreutz, C.L., Bacskai, B.J. & Hyman, B.T. (2010) Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J. Neurosci., 30, 2636-2649.
184. Yamada, K., Cirrito, J.R., Stewart, F.R., Jiang, H., Finn, M.B., Holmes, B.B., Binder, L.I., Mandelkow, E.M., Diamond, M.I., Lee, V.M. & Holtzman, D.M. (2011) In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci., 31, 13110-13117.
185. Yoshiyama, Y., Lee, V.M. & Trojanowski, J.Q. (2013) Therapeutic strategies for tau mediated neurodegeneration. J. Neurol. Neurosur. Ps., 84, 784-795.
186. Yuan, A., Kumar, A., Sasaki, T., Duff, K. & Nixon, R.A. (2013) Axonal transport rates in vivo are unaltered in Htau mice. J. Alzheimers Dis., 37, 579-586.
187. Zahs, K.R. & Ashe, K.H. (2010) 'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci., 33, 381-389.
188. Zahs, K.R. & Ashe, K.H. (2013) β-Amyloid oligomers in aging and Alzheimer's disease. Front. Aging Neurosci., 5, 28.
189. 2+ channels reduces alzheimer disease β-amyloid peptide secretion. J. Biol. Chem., 288, 26955-26966.
190. 2+ elevation, missorting of endogenous tau into dendrites, tau phosphorylation, and destruction of microtubules and spines. J. Neurosci., 30, 11938-11950.
191. Zempel, H., Luedtke, J., Kumar, Y., Biernat, J., Dawson, H., Mandelkow, E. & Mandelkow, E.M. (2013) Amyloid-β oligomers induce synaptic damage via tau-dependent microtubule severing by TTLL6 and spastin. EMBO J., 32, 2920-2937.
192. Zhao, W.-Q., Santini, F., Breese, R., Ross, D., Zhang, X.D., Stone, D.J., Ferrer, M., Townsend, M., Wolfe, A.L., Seager, M.A., Kinney, G.G., Shughrue, P.J. & Ray, W.J. (2010) Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors prevents amyloid beta oligomer-induced synaptic disruption. J. Biol. Chem., 285, 7619-7632.